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ABSTRACT
Dysregulated functions of B1 cells have been implicated in the disease progression 
of various autoimmune disorders, but it remains largely unclear whether B1 cells 
are involved in the pathogenesis of autoimmune arthritis. In this study, we found 
that peritoneal B1a cells underwent proliferation and migrated to the inflamed joint 
tissue with upregulated RANKL expression during collagen-induced arthritis (CIA) 
development in mice. Adoptive transfer of B1a cells exacerbated arthritic severity and 
joint damage while intraperitoneal depletion of B1 cells ameliorated both arthritic 
symptoms and joint pathology in CIA mice. In culture, RANKL-expressing B1a cells 
significantly promoted the expansion of osteoclasts derived from bone marrow cells, 
which were in accord with the in vivo findings of increased osteoclastogenesis in 
CIA mice transferred with B1a cells. Together, these results have demonstrated a 
pathogenic role of B1a cells in the development of autoimmune arthritis through 
RANKL-mediated osteoclastogenesis.
INTRODUCTION
Recent studies have identified the important 
contribution of conventional B (B2) cells to the 
development of autoimmune disease, but our current 
understanding for the role of B1 cells in autoimmune 
pathogenesis is still limited [1, 2]. B1 cells are 
distinguished from conventional B2 cells by their 
developmental origin, self-renewal capacity, anatomical 
location and phenotypic feature. B1 cells express high 
levels of CD19, IgM and CD11b, and can be further 
divided into CD5+ B1a and CD5- B1b subsets. Although 
B1 cells have been recognized for their protective 
functions against viruses, bacteria and parasites by 
producing natural IgM antibodies [3], increasing evidence 
indicates that B1 cells, especially the highly polyspecific 
B1a cells, play a role in autoimmune pathogenesis [4]. In 
mice, B1 cells mainly reside in the peritoneal and pleural 
cavities, but aberrant B1a cell migration has been found 
in the pancreas of non-obese diabetic (NOD) mice [5], 
and in the kidney, thymus and lung of NZBW F1 mice 
[6-8]. Remarkably, depletion of B1a cells by osmotic 
pressure ameliorates the development of type I diabetes 
[5], and reduces renal injury after kidney ischemia or 
reperfusion [9], indicating the involvement of B1a cells 
in disease progression. Early reports have found increased 
CD5+ B cells in patients with rheumatoid arthritis (RA) 
[10, 11], Sjögren’s syndrome [12] and systemic lupus 
erythematosus (SLE) [7, 13, 14]. Recent studies have 
characterized the human counterpart of murine B1 cells 
with the phenotype of CD20+CD43+CD27+CD70- present 
in the umbilical cord and adult peripheral blood [15]. 
Notably, the frequency of these B1 cells is markedly 
elevated in SLE patients and correlated with disease 
pathogenesis and pathopersistence [13].
B1 cells, in particular B1a cells, have been shown to 
contribute to autoimmune pathogenesis by autoantibody 
production [7, 8], antigen presentation and activation of 
CD4 T cells [7, 16], as well as cytokine production [17]. 
Recent evidence indicates that aberrant B1a cell trafficking 
is closely correlated with murine lupus progression, a 
process stimulated by the CXCL13-CXCR5 axis [6]. In 
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addition, B1a cells are found to migrate out of peritoneal 
cavity (PC) to the spleen, thymus and kidney and produce 
anti-dsDNA IgG antibodies in NZB/W F1 mice [8]. 
Furthermore, B1a cells not only activate autoreactive CD4 
T cells by its potent antigen-presenting activity, but also 
preferentially promote Th1 and Th17 cell differentiation 
and inhibit Treg cell differentiation [16, 18]. Although 
current studies have revealed the involvement of B1a 
cells in the pathogenesis of murine lupus and autoimmune 
diabetes, it is largely unclear whether and how B1a cells 
participate in the development of autoimmune arthritis. 
In this study, we found that peritoneal B1a cells 
underwent proliferative expansion and subsequently 
migrated to the inflamed joint tissue with upregulated 
RANKL expression in mice with collagen-induced 
arthritis (CIA). Moreover, adoptive transfer of B1a 
cells markedly exacerbated the arthritic severity and 
joint damage while intraperitoneal B1 cell depletion 
ameliorated disease progression in CIA mice. Thus, our 
results have demonstrated a pathogenic role of B1a cells 
in the development of autoimmune arthritis.
RESULTS
B1a cells undergo proliferative expansion during 
CIA development
To examine the kinetic changes of peritoneal B1 
cells during CIA development, CD19+CD11b+B220+ 
B1 cells from peritoneal lavage were analyzed by flow 
cytometry at various time intervals after CII-immunization 
(Figure 1A). The frequency of CD5+ B1a cells started 
to increase on day 7 post 1st CII-immunization (dpi). 
Accordingly, total numbers of peritoneal B1a cells were 
significantly increased on 7 dpi, reached a peak on 14 
dpi and followed by a gradual reduction from 21 dpi 
onward (Figure 1B). To determine whether the increased 
number of B1a cells was due to proliferative expansion, 
CFSE was injected into the PC of CII-immunized mice. 
The proliferative rate of B1a cells was determined by 
measuring the diluted CFSE fluorescence intensity with 
flow cytometry (Figure 1C). Remarkably, the proliferative 
rate of B1a cells was rapidly increased during CIA 
progression. (Figure 1D). These results indicated that B1a 
cells underwent proliferative expansion in the peritoneum 
during the development of CIA.
B1a cells migrate from peritoneal cavity to the 
inflamed joint tissue of CIA mice
Since gradually decreased numbers of peritoneal B1a 
cells were observed from 14 dpi onward, we hypothesized 
that B1a cells may migrate from peritoneal cavity to 
peripheral lymphoid organs or joint tissue of CIA mice. To 
test this hypothesis, sorting-purified B1a cells were labeled 
with CFSE and injected into the PC of DBA mice followed 
by CII immunization for CIA induction. On day 17 post 
CFSE+ B1a cell transfer, cell suspensions prepared from 
spleen (SP), draining lymph nodes (LN) and joint tissue 
were examined by flow cytometry. As expected, a discrete 
population of CFSE+ B1a cells was detected in the SP, LN 
and joint tissue, respectively (Figure 2A). Notably, CFSE+ 
B1a cells detected in the joint tissue showed the highest 
proliferative rate when compared with those from SP and 
LN (Figure 2A). Moreover, CFSE+ B1a cells were mainly 
accumulated in the synovium of knee joint as detected by 
immunofluorescent microscopy (Figure 2B). Interestingly, 
we detected markedly increased expression of CXCR5 on 
peritoneal B1a cells at both mRNA and protein levels from 
CIA mice when compared with DBA controls (Figure 2C 
and 2D). In addition, increased CXCL13 expression was 
detected in the synovial tissue of CIA mice compared 
with DBA mice (Figure 2E). These findings suggested 
a possible role of CXCL13-CXCR5 axis in B1a cells 
migration to the inflamed joint tissue. 
B1a cell transfer or depletion modulates CIA 
progression
To determine a role of B1a cells in the development 
of CIA, sorting-purified peritoneal CD19+CD11b+CD5+ 
B1a cells were intraperitoneally transferred to 2nd CII-
immunized DBA mice on 21 dpi, followed by monitoring 
the development of arthritic symptoms and histopathology 
of joint damage (Figure 3A). CIA mice with B1a cell 
transfer displayed exacerbated arthritis development 
with an earlier disease onset and higher clinical scores 
of arthritis symptoms when compared to PBS-treated 
CIA mice (Figure 3B). Further assessment of synovial 
hyperplasia, cartilage damage and bone erosion in joint 
tissue revealed that B1a-transferred CIA mice exhibited 
more pronounced joint damage with significantly higher 
histopathological scores when compared with PBS-
treated CIA controls (Figure 3C). To further determine 
whether peritoneal B1 cell depletion may ameliorate 
the development of CIA, we performed intraperitoneal 
Milli-Q water injection for B1 cell depletion using a 
previously reported protocol (Supplementary Figure 1A) 
[5, 9]. As a result, both frequency and number of peritoneal 
CD19+CD11b+ B1 cells were markedly reduced in water-
injected mice compared with PBS-injected controls, 
especially the CD19+CD11b+B220+CD5+ B1a cells 
(Figure 3D and Supplementary Figure 1B). Consistently, 
total numbers of CD19+CD43+ B1 and CD19+CD43+CD5+ 
B1a cells in the joint tissue were drastically decreased in 
B1-depleted CIA mice when compared to PBS-treated 
CIA mice (Supplementary Figure 1C). Interestingly, 
both the incidence of arthritic development and clinical 
scores of disease severity were significantly lower in 
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Figure 1: B1a cells undergo proliferative expansion in the peritoneal cavity (PC) during CIA development. A. Flow 
cytometric analysis of CD19+B220+CD11b+CD5+ B1a cells in the PC of DBA and CIA mice on day 14 post 1st CII-immunization. Flow 
profiles are representative from five independent experiments. B. Frequencies and total numbers of CD19+B220+CD11b+CD5+ B1a from 
the PC of CIA mice were determined by flow cytometry at various time intervals after CII-immunization. Data are derived from five 
independent experiments and shown as mean ± SD (*, p < 0.05, **, p < 0.01, ***, p < 0.001). C. CFSE was intraperitoneally injected 
into DBA mice and followed by CII immunization for CIA induction. The proliferation of CD19+CD11b+ B1 cells on day 14 post 1st 
immunization were determined by flow cytometric analysis. D. CFSE-positive CD19+B220+CD11b+CD5+ B1a cells in the PC at various 
time intervals after CII-immunization were measured by flow cytometry. The indicated percentages in C and D are representative of three 
independent experiments with similar results. 
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Figure 2: B1a cells migrate from PC to the joint tissue of CIA mice. A. Sorting-purified peritoneal B1a cells were stained 
with CFSE and intraperitoneally transferred into DBA mice and followed by CII immunization for CIA induction. On day 17 after cell 
transfer, CFSE+ B1a cells in cell suspensions from the spleen (SP), draining lymph nodes (LN) and joint tissues (Jt) were detected by flow 
cytometry. Flow profiles are representative from three independent experiments. B. CFSE+ B1a cells accumulated in the synovium of knee 
joint of B1a-transferred CIA mice were detected by confocal microscopy (n = 5). Scale bar, 50 μm. C., D. CXCR5 expression on peritoneal 
B1a cells from DBA and CIA (14 dpi) mice were measured by q-PCR in C and flow cytometry in D (n = 6). Data in C were shown as 
mean ± SD (***, p < 0.001). E. CXCL13 expression in the synovium of knee joints of DBA and CIA mice on 17 dpi were measured by 
immunohistochemistry (IHC) staining. Nucleus was stained with hematoxylin solution. CXCL13-expressing cells are stained an intense 
brown (Original magnification, ×100) (n = 5).
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B1-depleted CIA mice than PBS-injected CIA controls 
(Figure 3E). Importantly, B1 cell depletion attenuated the 
joint pathology with decreased synovial hyperplasia and 
bone damage in CIA mice (Figure 3F). Together, these 
results demonstrated a pathogenic role of B1a cells in the 
development of CIA.
B1a cells express RANKL in the joint of CIA mice
In patients with RA, B cells from the synovial cavity 
were found to express high levels of RANKL [19], but 
the functional implication of RANKL-producing B cells 
remained to be addressed. Previous studies showed that 
B1 cells downregulate CD11b and upregulate CD43 
Figure 3: Intraperitoneal transfer or depletion of B1a cells influences CIA progression. A. Schematic description for CIA 
induction and time points of B1a cell transfer, and data collection. Sorting-purified peritoneal CD19+B220+CD11b+CD5+ B1a cells (1×106) 
from CII-immunized DBA mice on 7 dpi were intraperitoneally transferred to recipient CIA mice on 21 dpi. Control CIA mice were 
intraperitoneally injected with the same volume of PBS. Both incidences of arthritis development and clinical scores were analyzed. B. 
Cumulative CIA incidence (100%) and mean clinical score of PBS-treated and B1a cell-transferred CIA mice were calculated daily (five 
independent experiments, n = 7 per group in each experiment). C. Histopathologic examination of joint samples from B1a cell-transferred 
CIA mice and PBS-treated CIA controls in B on day 30 post 1st CII-immunization (H&E staining, original magnification, ×100). Data of 
histological scores at the right panel are shown as mean ± SD. (n = 5 per group, *, p < 0.05, **, p < 0.01). D. B1 cells were depleted by 
intraperitoneal injection of distilled water every two days for five times from day 17 after 1st CII-immunization (17-25 dpi) whereas control 
mice were treated with the same volume of PBS injected into the PC of CIA mice. The depletion efficacy of CD19+CD11b+ B1 cells and 
CD19+CD11b+CD5+ B1a cells in the PC of PBS-injected and B1 cell-depleted mice were determined by flow cytometry. Data derived from 
five independent experiments (n = 7-10 per group in each experiment) are shown as mean ± SD (*, p < 0.05, **, p < 0.01, ***, p < 0.001). 
E. Both cumulative arthritis incidences and mean clinical scores of PBS-treated CIA mice and B1-depleted CIA mice were calculated from 
five independent experiments (n = 7-10 per group in each experiment). F. Histopathologic examination of joint tissue from PBS-injected 
CIA mice and B1-depleted CIA mice on day 40 post 1st CII-immunization with H&E staining (original magnification, ×100) (n = 5 per 
group). Data are shown as mean ± SD (*, p < 0.05). 
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Figure 4: B1a cells express RANKL in the inflamed joint of CIA mice. A., B. Flow cytometric analysis of RANKL expression 
on CD19+CD43- B2 and CD19+CD43+ B1 cells in A, CD19+CD43+CD5+ B1a and CD19+CD43+CD5- B1b cells in B in the inflamed joint 
of CIA mice on day 30 post 1st CII-immunization. C. The frequencies of RANKL+ B2, B1, B1a and B1b cells were enumerated from three 
independent experiments (n = 5-7 per group in each experiment). D. Peritoneal B1a cells from CD45.1+ BoyJ mice were intraperitoneally 
transferred into CD45.2+ C57 mice and followed by CII immunization for CIA induction. On day 17 after cell transfer, RANKL expression 
on donor CD45.1+ B1a cells in the PC, SP, LN and joint tissue (Jt) were detected by flow cytometry. The flow profiles are representative 
data from three independent experiments with similar results.
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expression upon their egress from peritoneal cavity. 
CD43 was used as a maker for identifying B1 cells 
outside of peritoneal and pleural cavities in this study [20-
22]. To characterize the functional features of B cells in 
the inflamed joint of CIA mice, we detected significant 
RANKL expression on synovial B cells, with a 7-fold 
higher frequency of RANKL-expressing CD19+CD43+ B1 
than that of CD19+CD43+ B2 cells (Figure 4A). Moreover, 
the frequency of RANKL-expressing CD19+CD43+CD5+ 
B1a cells was approximately 12-fold higher than that of 
CD43+CD5- B1b cells (Figure 4B and 4C). To further 
confirm the expression of RANKL on migrated B1a 
cells in the joint tissue, CD45.1+ B1a cells from the PC 
of naive BoyJ mice were intraperitoneally transferred to 
CD45.2+ C57 mice, followed by CII-immunization for 
CIA induction. Although only less than 1% of sorting-
purified CD45.1+ B1a cells expressed RANKL prior to 
transfer, more than 60% of CD45.1+ B1a cells expressed 
high level of RANKL in the joint tissue on day 17 post 
transfer (Figure 4D). These results demonstrated that 
B1a cells were the major RANKL-expressing cell subset 
among synovial B cells in the joint tissue of CIA mice. 
IL-1β and IL-6 induce RANKL expression on B1a 
cells
To determine the inflammatory cytokines involved 
in inducing RANKL expression on B1a cells in the joint, 
we detected markedly increased levels of IL-1β and IL-6 
transcripts in the synovium of CIA mice compared with 
DBA controls (Figure 5A). In addition, flow cytometric 
analysis detected the expression of both IL-1β receptor 
(IL-1R) and IL-6 receptor (IL-6R) on peritoneal B1a cells 
(Figure 5B). In culture, treatment with either IL-1β or 
IL-6 significantly increased both the percentage and total 
numbers of RANKL+ B1a cells. Moreover, treatment with 
IL-1β plus IL-6 showed synergistic effects in inducing 
RANKL expression on B1a cells (Figure 5C, 5D). In 
accordance with the in vitro studies, flow cytometric 
analysis revealed the expression of IL-1R and IL-6R on 
B1a cells in the joint tissue (Supplementary Figure 2A). 
We also detected upregulated IL-1β and IL-6 in F4/80+ 
cells in joint tissues after CIA induction (Supplementary 
Figure 2B), suggesting the critical role of IL-1β and IL-6 
in the induction of RANKL expression on B1a cells in 
the inflamed joint. Collectively, these findings showed that 
proinflammatory cytokines IL-1β and IL-6 could induce 
RANKL expression on B1a cells.
RANKL-expressing B1a cells promote 
osteoclastogenesis from bone marrow cells
Next, we investigated whether RANKL-expressing 
B1a cells could induce osteoclastogenesis in vitro. Bone 
marrow cells (BMCs) were first cultured with M-CSF for 
3 days. Then, IL-1β- and IL-6-stimulated B1a cells were 
cocultured with M-CSF-treated BMCs for 5 days. We 
found that IL-1β- and IL-6-stimulated B1a cells markedly 
promoted osteoclast differentiation and maturation when 
compared with freshly isolated B1a cells (Figure 6A and 
6B). Consistently, CIA mice transferred with B1a cells 
exhibited significantly increased numbers of osteoclasts in 
the joint tissue with exacerbated bone erosion. In contrast, 
CIA mice with B1 depletion displayed substantially 
decreased numbers of osteoclasts in joint tissue with 
ameliorated bone erosion when compared with PBS-
treated mice (Figure 6C). These results indicated that 
synovial RANKL-expressing B1a cells could promote 
osteoclastogenesis both in vitro and in vivo.
DISCUSSION
In this study, we show that peritoneal B1a cells 
undergo proliferative expansion and migrate to peripheral 
lymphoid organs and inflamed joint tissue during the 
development of murine CIA. Moreover, adoptive transfer 
of B1a cells exacerbates arthritis progression while 
depletion of peritoneal B1 cells ameliorates disease 
severity and joint pathology in CIA mice. Inflammatory 
cytokine IL-1β and IL-6 significantly upregulated 
RANKL expression on B1a cells which consequently 
possessed potent capability to induce osteoclastogenesis 
of bone marrow-derived osteoclasts. Together, these 
findings demonstrate a pathogenic role of B1a cells in the 
pathogenesis of autoimmune arthritis.
With unique developmental origin and anatomical 
location, B1 cells are characterized as a separate lineage 
of B cells [3]. There is increasing evidence that B1 cells 
are involved in the development of various autoimmune 
diseases [4]. In a recent report, Siglec-G deficient mice 
show an expansion of B1 cell compartment and exhibit 
increased severity of arthritic symptoms and join 
inflammation upon CIA induction [23]. Early studies have 
revealed that aberrant trafficking of B1a cells is correlated 
with the disease progression of murine lupus [6, 7, 14]. 
B1 cells have been found to migrate into the thymus and 
stimulate the proliferation of autoreactive CD4 T cells via 
potent antigen-presenting activity [7]. Here, we show that 
peritoneal B1a cells during CIA development undergo 
proliferative expansion before their egress out of PC as 
revealed by CFSE- live cell staining and flow cytometric 
analysis. Although it remains currently unclear which 
factors contribute to the egress of B1 cells from PC during 
arthritic progression, previous studies have demonstrated 
that B1 cell migration is activated by signals through toll-
like receptors that induce the downregulation of integrins 
and CD9 [24]. Several endogenous ligands including 
HMGB1 have been identified to activate TLR4 [25]. 
Thus, it is reasonable to speculate that endogenous ligands 
for TLR4 may be involved in promoting B1a cell egress 
during CIA progression. By intraperitoneally transferring 
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Figure 5: IL-1β and IL-6 induce RANKL expression in B1a cells. A. Levels of Il1b and Il6 transcripts in the synovium of knee 
joints of DBA and CIA mice were measured by q-PCR. Data are derived from three independent experiments and shown as mean ± SD. (n 
= 5 per group, **, p < 0.01, ***, p < 0.001). B. IL-1β receptor (IL-1R) and IL-6 receptor (IL-6R) expression on B1a cells from PC of DBA 
mice were measured by flow cytometric analysis (n = 5). C. B1a cells from PC of DBA mice were cultured with medium alone, or with 
medium containing IL-1β, IL-6 and IL-1β + IL-6 for 2 days. RANKL expression on cultured B1a cells were examined by flow cytometric 
analysis and representative flow cytometric profiles are shown (n = 3). D. Both frequencies (upper histogram) and total numbers (lower 
histogram) of cultured RANKL+ B1a cells in (C) were calculated from 5 separate experiments. Data are shown as mean ± SD (*, p < 0.05, 
**, p < 0.01, ***, p < 0.001).
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CFSE-labeled B1a cells, we have detected the migration 
of peritoneal B1a cells to the spleen, draining lymph 
node and inflamed joint tissue of CIA mice. It is likely 
that markedly increased levels of CXCL13 expression 
in the synovial tissue of CIA mice may contribute to the 
chemotactic attraction of peritoneal B1a cells, a notion 
supported by previous findings that the CXCL13-CXCR5 
axis is responsible for the aberrant trafficking of B1a cells 
to the kidney in murine lupus [6].
Recent studies suggest that the functional changes 
of B1a cells may result from their aberrant trafficking to 
the peripheral lymphoid organs and sites of inflammation 
during infection and autoimmunity [3, 4]. Previous studies 
have shown that B1a cells secrete low level of GM-CSF 
Figure 6: RANKL-expressing B1a cells promote osteoclastogenesis both in vitro and in vivo. A. Bone marrow cells (BMCs) 
were cultured with M-CSF for 3 days and then cocultured with medium only, freshly prepared B1a cells, IL-1β+IL-6 stimulated B1a 
cells, or medium containing RANKL (20 ng/ml) for 2 days. Osteoclasts were identified by tartrate-resistant acid phosphatase (TRAP) 
staining (original magnification, ×200). B. Cell numbers of TRAP+ multinucleated cells (more than three nuclei) were enumerated from 
five independent experiments. Data are shown as mean ± SD (n = 5, *, p < 0.05, ***, p < 0.001). C. Osteoclasts in the joint tissue of B1a 
transferred CIA mice and PBS-treated CIA mice were identified by H&E in upper panel (black arrow indicated multinucleated cells) and 
TRAP staining in lower panel (black arrow indicated brown multinucleated cells), respectively (n = 5) (original magnification, ×200).
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in the PC, but B1a cells proliferate and increase GM-
CSF production once they migrate to the spleen or are 
activated with LPS [26]. Notably, we have identified 
a population of RANKL-expressing B1a cells that are 
gradually increased in frequencies from peripheral 
lymphoid organs to inflamed joint tissue upon their 
egress from PC. During arthritic progression, activated 
synoviocytes produce an array of inflammatory cytokines 
involved in joint pathology in CIA mice. As expected, 
increased levels of IL-6 and IL-1β transcript expression 
are detected in inflamed joint tissue where local B1a cells 
express upregulated IL-1β and IL-6 receptors. In culture, 
both IL-1β and IL-6 show significant effects on inducing 
RANKL expression in B1a cells. When CD45.1+ B1a cells 
are intraperitoneally transferred into CD45.2+ C57 mice 
followed by CII-immunization for CIA induction, we have 
subsequently detected markedly increased frequency of 
RANKL-expressing CD45.1+ B1a cells in the joint tissue, 
which provide further evidence that local inflammatory 
cytokines can enhance the functional changes of B1 cells 
in situ.
RANKL is known to be responsible for osteoclast 
differentiation and activation [27], many studies have 
demonstrated an important role of RANKL-producing T 
cells in driving joint pathologies during the development 
of autoimmune arthritis in mice and RA patients [28]. 
Although B cells have been recently identified as the main 
source of RANKL in the synovial fluid of RA patients, 
it remains to be verified whether B1 cells reside within 
this RANKL-expressing B cell population [19, 29]. Up 
to date, the mediators that drive RANKL expression in 
B cells and the potential role of RANKL-producing B 
cells in osteoclastogenesis have been poorly investigated 
[30]. Here, we first show that frequency of RANKL+ 
B1 cells is 7-fold higher than RANKL+ B2 cells among 
synovial B cells from CIA mice. Moreover, RANKL+ 
B1 cells in synovial tissue are predominantly B1a 
cells. In culture, RANKL+ B1a cells can significantly 
promote osteoclast differentiation from bone marrow 
cells, which are in accord with in vivo findings that CIA 
mice with B1a cell transfer exhibit increased osteoclast 
activity with exacerbated bone erosion when compared 
with control CIA mice. Although our findings suggest a 
novel role of RANKL-expressing B1a cells in inducing 
osteoclastogenesis during arthritic progression, further 
studies on blocking RANKL expression on B1 cells are 
need to define the role of RANKL expressed on B1a cells 
in osteoclastogenesis. 
There is growing evidence that multifaceted 
functions of B1 cells other than antibody production are 
implicated in the development of autoimmune diseases 
including autoimmune diabetes, lupus and Sjögren’s 
syndrome [6-8, 10-14]. Although the mechanisms by 
which B1 cells contribute to the pathogenesis of RA 
remain to be further investigated, our current studies 
have clearly demonstrated a pathogenic role of B1a cells 
in the development of murine autoimmune arthritis. 
Future clinical investigations will provide new insights 
in understanding the role of B1 cells in the pathogenesis 
of RA, which may potentially lead to the development of 
targeting B1 cells as new therapy for RA treatment.
MATERIALS AND METHODS
Mice, CIA induction and assessment
DBA/1J, C57BL/6 (CD45.2) and congenic B6.SJL-
PtprcaPepcb/BoyJ (CD45.1) mice were purchased from 
the Jackson Laboratory and maintained in a specific 
pathogen-free animal facility at the University of Hong 
Kong with access to food and water ad libitum. All 
animal experiments were approved by the Committee 
on the Use of Live Animals in Teaching and Research 
of the University of Hong Kong. Mice were immunized 
with bovine collagen II (CII) emulsified in Complete 
Freund Adjuvant and boosted with CII in Incomplete 
Freund Adjuvant on day 21 after the first immunization 
for CIA induction while mice immunized with Freund’s 
adjuvant alone served as controls [31]. The incidence and 
clinical score of CIA were observed daily upon 2nd CII-
immunization. For the joint histopathologic examination, 
paraffin-embedded joint tissue sections were stained with 
hematoxylin and eosin (H&E) and assessed by a light 
microscopy (Eclipse E 800, Nikon).
Cell culture and TRAP staining
Bone marrow cells (BMCs) from DBA mice were 
cultured with M-CSF (10 ng/ml) in a 96-well plate (1×105 
cells per well) for 3 days. Peritoneal B1a cells were 
cultured in a 96-well plate (1×105) with medium alone, 
or medium containing IL-1β, IL-6 and IL-1β plus IL-6, 
respectively, for 2 days. Then, IL-1β plus IL-6 stimulated 
B1a cells were cocultured with M-CSF-stimulated BMCs 
for 5 days. Osteoclasts were stained with tartarate-
resistant acid phosphatase (TRAP, Sigma) following the 
manufacturer’s instructions, which were identified as 
TRAP-positive multinucleated cells (MNCs) with the 
morphology of large multinucleated (more than 2 nuclei 
per cell) and distinct nucleoli, and coarse azurophilic 
granules in cytoplasm. The number of TRAP+ MNCs was 
counted at predetermined sites in an area of 1 × 1 mm 
using a light microscope. Five wells with five sites per 
well were measured in total. 
Cell sorting and flow cytometric analysis
After preparing single-cell suspensions from the 
spleen and peritoneal lavage, the cells were stained with 
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FITC-, phycoerythrin (PE)-, phycoerythrin-Cyanin 7 
(PE-Cy7)-, allophycocyanin (APC)- and PerCP-Cy5.5- 
conjugated mAbs against CD19, CD11b, B220, CD5, 
CD43 and RANKL for cell sorting (FACSAria II cell 
sorter, BD Biosciences) or flow cytometric analysis 
(Fortessa, BD Biosciences). The gating strategy used to 
purify peritoneal CD19+B220+CD11b+CD5+ B1a cells 
were adopted from a previously reported protocol with 
slight modification [32]. In brief, B1a cells were gated 
on the singlets determined by FSC-A/FSC-H gating to 
remove doublets. B1a cells with the purity >97% were 
used for culture and transfer experiments.
B1a cell transfer and intraperitoneal B1 cell 
depletion
Sorting-purified CD19+B220+CD11b+CD5+ B1a 
cells were intraperitoneally transferred into recipient 
DBA mice on day 21 post 1st CII-immunization whereas 
control mice were intraperitoneally injected with the same 
volume of PBS. Using a previously reported protocol for 
peritoneal B1a cell depletion [5, 9], Milli-Q water (2 ml 
per mice for each injection) was intraperitoneally injected 
into mice on days 17-27 post 1st CII-immunization. 
Control mice were intraperitoneally injected with the same 
volume of PBS (2 ml per mice for each injection). The 
depletion efficacy of B1 cells in the peritoneum and joint 
tissues was determined by flow cytometry.
CFSE labeling and monitoring of B1 cell 
migration
Proliferation of peritoneal B1a cell was determined 
by carboxyfluorescein succinimidyl ester (CFSE) in situ 
detection using a previously reported protocol with slight 
modification [33]. Briefly, CFSE dissolved in 2 ml of PBS 
(30 μg/ ml) was intraperitoneally injected into mice on 
day 21 post 1st CII-immunization, followed by 2nd CII 
immunization for CIA induction. On day 17 post 2nd CII 
immunization, CFSE-positive cells in the peritoneal cavity 
(PC), spleen (SP), draining lymph nodes (LN) and joint 
tissues (Jt) were determined by flow cytometric analysis. 
To measure B1a cell migration to the joint tissue, purified 
B1a cells from the PC of BoyJ (CD45.1+) mice were 
intraperitoneally transferred into C57 (CD45.2+) mice 
followed by CII-immunization for CIA induction. On day 
17 post transfer, RANKL expression on CD45.1+ B1a cells 
isolated from joint tissue was examined by flow cytometry.
Immunofluorescent (IF) and 
immunohistochemical (IHC) staining
Mouse joint samples were fixed, decalcified, 
embedded with optimum cutting temperature (OCT, 
Tissue-Tek) and cut into 6 μm sections. Sections were 
stained with DAPI to detect CFSE+ B1a cells in the 
synovium of knee joint using a confocal microscopy 
(LSM 710, Zeiss). CXCL13 expression in the synovium 
of knee joint was detected by immunohistochemical 
staining. Paraffin-embedded sections of joint tissue 
were deparaffinized and rehydrated. After endogenous 
peroxidase inhibition by 0.5% hydrogen peroxide, 
sections were blocked with rabbit serum and incubated 
with biotinylated rabbit anti-mouse CXCL13 (Abcam). 
CXCL13-expressing cells were identified with 
StreptABComplex/HRP (Dako) and 3,3-diaminobenzidine 
tetrahydrochloride solution (Sigma-Aldrich) to develop 
brown precipitates.
Statistical analysis
The statistical significance of differences between 
groups was determined by Student’s t-tests. Data were 
analyzed with Prism (version 5.0, GraphPad Software) and 
shown as mean ± SD. A value of P < 0.05 was considered 
statistically significant. 
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